US 11,723,929 B2
Methods of improving cell-based therapy
Nipavan Chiamvimonvat, Davis, CA (US); Bruce D. Hammock, Davis, CA (US); and Padmini Sirish, Davis, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 16/621,649
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Jun. 11, 2018, PCT No. PCT/US2018/036891
§ 371(c)(1), (2) Date Dec. 11, 2019,
PCT Pub. No. WO2018/231702, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/519,092, filed on Jun. 13, 2017.
Prior Publication US 2021/0145891 A1, May 20, 2021
Int. Cl. C12N 5/074 (2010.01); A61K 35/34 (2015.01); A61K 31/453 (2006.01); A61K 45/06 (2006.01); A61L 31/16 (2006.01)
CPC A61K 35/34 (2013.01) [A61K 31/453 (2013.01); A61K 45/06 (2013.01); A61L 31/16 (2013.01); C12Y 303/0201 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of increasing, improving and/or promoting the survival, engraftment, and/or integration of transplanted stem cells in a tissue of a subject in need thereof, comprising:
a) exposing a population stem cells in vitro to an agent that increases the production and/or level of epoxy fatty acids (EpFA), or mimics thereof, under conditions and for a time sufficient to increase epoxy fatty acids (EpFA) and/or inhibit soluble epoxide hydrolase in the stem cells, thereby producing preconditioned stem cells; and
b) administering to the subject the preconditioned stem cells, wherein the stem cells are selected from multipotent stem cells, pluripotent stem cells, and induced pluripotent stem cells.